Related Experiment Video

Updated: Mar 3, 2026

Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

2.8K

A New Perspective on Predicting PLA2R-Associated Membranous Nephropathy Relapse: The Value of a Genetic Risk Score

Xiaolong Wang1, Kexin Yao1, Yue Niu1

  • 1Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases, Beijing, People's Republic of China.

Journal of Inflammation Research
|March 2, 2026
PubMed
Abstract

Insights

A new genetic risk score (GRS) effectively predicts relapse in phospholipase A2 receptor (PLA2R)-associated membranous nephropathy (MN). This GRS tool aids in personalized risk assessment for patients with this common glomerular disease.

Area of Science:

  • Nephrology
  • Genetics
  • Glomerular Diseases

Background:

  • Membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults.
  • High relapse rates and variable patient outcomes complicate MN management.
  • Phospholipase A2 receptor (PLA2R)-associated MN accounts for the majority of primary MN cases.

Purpose of the Study:

  • To develop a genetic risk score (GRS) using MN-associated single nucleotide polymorphisms (SNPs).
  • To evaluate the predictive capability of the GRS for disease relapse in PLA2R-associated MN.
  • To assess the GRS's utility in enhancing personalized risk stratification for MN patients.

Main Methods:

  • A prospective cohort of 234 PLA2R-associated MN patients was analyzed.
  • Genotyping was performed for five established MN-risk SNPs.
  • A GRS was constructed, and Cox regression models assessed relapse risk.
  • Predictive performance was validated using time-dependent ROC curves, reclassification, and model fit metrics.

Main Results:

  • A high GRS was significantly associated with an increased risk of MN relapse (HR=1.885, P<0.001).
  • The GRS improved predictive accuracy across multiple years, as evidenced by AUC, NRI, and IDI.
  • Model fit statistics (LRT, AIC, BIC) and cross-validation confirmed the GRS's robust predictive performance.

Conclusions:

  • This study introduces the first GRS for predicting relapse in PLA2R-associated MN.
  • The GRS significantly enhances the accuracy of relapse prediction in MN.
  • The developed GRS serves as a valuable tool for personalized risk assessment and management of MN.
Keywords:
SNPgenetic risk scoremembranous nephropathyrelapse

More Related Videos

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

15.8K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
65
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56